26.10.2021 – 20:47
BOGOTA, Colombia, Jan.
BIOPAS, a leading, one-of-a-kind Latin American biopharmaceutical company focused on the in-licensing and commercialization of specialty drugs, excluding generic and branded drugs, that meet unmet medical needs in the region, today announced the launch of its Brazilian operations, the from November with the exclusive distribution of RIVOTRIL® begins, thereby expanding its ongoing strategic collaboration with CHEPLAPHARM ARZNEIMITTEL GmbH out on Brazil.
This step strengthens the position of BIOPAS as the exclusive one-stop-shop provider for specialty drugs in the entire region.
The turnkey solution from BIOPAS aims as preferred partner Providing market exposure and growth opportunities to international pharmaceutical companies and providing patients in Latin America with access to innovative treatments.
The unmatched market access tools from BIOPAS and the associated revenue opportunities significantly reduce the complexity, organizational management issues, and time investment generally associated with country-specific transactions.
Information on biopas
BIOPAS (www.biopasgroup.com) is a leading Latin American differentiated pharmaceutical company specializing in the in-licensing, marketing and distribution of state-of-the-art, specialty prescription drugs.
The business model of BIOPAS is specifically designed to provide market access to multiple therapeutic options to meet the unmet medical needs of the Latin American population. BIOPAS is a leader in the fields of CNS, immunology, dermatology, oncology and orphan drugs. The entire product portfolio of BIOPAS is licensed by its partners, excluding generics and / or branded generics.
Offers via its regional platform BIOPAS first class sales, marketing, medical and support services. The company’s highly talented and dedicated teams enable the successful introduction and development of innovative products. All activities of BIOPAS are in line with international standards and regulations.
BIOPAS has a long and successful history and has built long-term and fruitful relationships with its partners including UCB, FERRING, IPSEN, VERTEX and more recently CHIESI, CHEPLAPHARM and DAEWONG.
Margarita Castro Gomez
Original content by: Biopas, transmitted by news aktuell